Cargando…

Timing of therapies for Down syndrome: the sooner, the better

Intellectual disability (ID) is the unavoidable hallmark of Down syndrome (DS), with a heavy impact on public health. Accumulating evidence shows that DS is characterized by numerous neurodevelopmental alterations among which the reduction of neurogenesis, dendritic hypotrophy and connectivity alter...

Descripción completa

Detalles Bibliográficos
Autores principales: Stagni, Fiorenza, Giacomini, Andrea, Guidi, Sandra, Ciani, Elisabetta, Bartesaghi, Renata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594009/
https://www.ncbi.nlm.nih.gov/pubmed/26500515
http://dx.doi.org/10.3389/fnbeh.2015.00265
_version_ 1782393394011570176
author Stagni, Fiorenza
Giacomini, Andrea
Guidi, Sandra
Ciani, Elisabetta
Bartesaghi, Renata
author_facet Stagni, Fiorenza
Giacomini, Andrea
Guidi, Sandra
Ciani, Elisabetta
Bartesaghi, Renata
author_sort Stagni, Fiorenza
collection PubMed
description Intellectual disability (ID) is the unavoidable hallmark of Down syndrome (DS), with a heavy impact on public health. Accumulating evidence shows that DS is characterized by numerous neurodevelopmental alterations among which the reduction of neurogenesis, dendritic hypotrophy and connectivity alterations appear to play a particularly prominent role. Although the mechanisms whereby gene triplication impairs brain development in DS have not been fully clarified, it is theoretically possible to correct trisomy-dependent defects with targeted pharmacotherapies. This review summarizes what we know about the effects of pharmacotherapies during different life stages in mouse models of DS. Since brain alterations in DS start to be present prenatally, the prenatal period represents an optimum window of opportunity for therapeutic interventions. Importantly, recent studies clearly show that treatment during the prenatal period can rescue overall brain development and behavior and that this effect outlasts treatment cessation. Although late therapies are unlikely to exert drastic changes in the brain, they may have an impact on the hippocampus, a brain region where neurogenesis continues throughout life. Indeed, treatment at adult life stages improves or even rescues hippocampal neurogenesis and connectivity and hippocampal-dependent learning and memory, although the duration of these effects still remains, in the majority of cases, a matter of investigation. The exciting discovery that trisomy-linked brain abnormalities can be prevented with early interventions gives us reason to believe that treatments during pregnancy may rescue brain development in fetuses with DS. For this reason we deem it extremely important to expedite the discovery of additional therapies practicable in humans in order to identify the best treatment/s in terms of efficacy and paucity of side effects. Prompt achievement of this goal is the big challenge for the scientific community of researchers interested in DS.
format Online
Article
Text
id pubmed-4594009
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-45940092015-10-23 Timing of therapies for Down syndrome: the sooner, the better Stagni, Fiorenza Giacomini, Andrea Guidi, Sandra Ciani, Elisabetta Bartesaghi, Renata Front Behav Neurosci Neuroscience Intellectual disability (ID) is the unavoidable hallmark of Down syndrome (DS), with a heavy impact on public health. Accumulating evidence shows that DS is characterized by numerous neurodevelopmental alterations among which the reduction of neurogenesis, dendritic hypotrophy and connectivity alterations appear to play a particularly prominent role. Although the mechanisms whereby gene triplication impairs brain development in DS have not been fully clarified, it is theoretically possible to correct trisomy-dependent defects with targeted pharmacotherapies. This review summarizes what we know about the effects of pharmacotherapies during different life stages in mouse models of DS. Since brain alterations in DS start to be present prenatally, the prenatal period represents an optimum window of opportunity for therapeutic interventions. Importantly, recent studies clearly show that treatment during the prenatal period can rescue overall brain development and behavior and that this effect outlasts treatment cessation. Although late therapies are unlikely to exert drastic changes in the brain, they may have an impact on the hippocampus, a brain region where neurogenesis continues throughout life. Indeed, treatment at adult life stages improves or even rescues hippocampal neurogenesis and connectivity and hippocampal-dependent learning and memory, although the duration of these effects still remains, in the majority of cases, a matter of investigation. The exciting discovery that trisomy-linked brain abnormalities can be prevented with early interventions gives us reason to believe that treatments during pregnancy may rescue brain development in fetuses with DS. For this reason we deem it extremely important to expedite the discovery of additional therapies practicable in humans in order to identify the best treatment/s in terms of efficacy and paucity of side effects. Prompt achievement of this goal is the big challenge for the scientific community of researchers interested in DS. Frontiers Media S.A. 2015-10-06 /pmc/articles/PMC4594009/ /pubmed/26500515 http://dx.doi.org/10.3389/fnbeh.2015.00265 Text en Copyright © 2015 Stagni, Giacomini, Guidi, Ciani and Bartesaghi. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Stagni, Fiorenza
Giacomini, Andrea
Guidi, Sandra
Ciani, Elisabetta
Bartesaghi, Renata
Timing of therapies for Down syndrome: the sooner, the better
title Timing of therapies for Down syndrome: the sooner, the better
title_full Timing of therapies for Down syndrome: the sooner, the better
title_fullStr Timing of therapies for Down syndrome: the sooner, the better
title_full_unstemmed Timing of therapies for Down syndrome: the sooner, the better
title_short Timing of therapies for Down syndrome: the sooner, the better
title_sort timing of therapies for down syndrome: the sooner, the better
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594009/
https://www.ncbi.nlm.nih.gov/pubmed/26500515
http://dx.doi.org/10.3389/fnbeh.2015.00265
work_keys_str_mv AT stagnifiorenza timingoftherapiesfordownsyndromethesoonerthebetter
AT giacominiandrea timingoftherapiesfordownsyndromethesoonerthebetter
AT guidisandra timingoftherapiesfordownsyndromethesoonerthebetter
AT cianielisabetta timingoftherapiesfordownsyndromethesoonerthebetter
AT bartesaghirenata timingoftherapiesfordownsyndromethesoonerthebetter